Empowering mHealth Gazelles

•

0 likes•263 views

Ernst & Young LLP (EY) is a global professional services firm that has been in business since 1849. They work with many high-growth companies and have helped clients like Google grow from 5 employees to their current size. EY focuses on empowering "gazelle" companies, which are defined as fast-growing businesses. The presentation provides an example of how EY has helped one client grow from $0.0002 billion in revenue to $3.2 billion through IPO. It also discusses trends in healthcare innovation and provides three examples of mHealth companies that are focusing on connecting patients, doctors, and payers.

Health & Medicine Business Technology

Empowering
mHealth gazelles
E&Y’s hypergrowth companies practice (SGM)
@ mHealthCon, New Brunswick NJ

01 December 2011

Fast facts about
Ernst & Young LLP
Well-known facts:
► Been around a while: since 1849
(including predecessors)

► Global: 150,000+ people in
140+ countries
► Premiere Big4 accounting firm

Little-known facts:
► Entrepreneur of the Year for 25 years & Winning Women Entrepreneurs for 4 years
► Heavily involved with emerging economy entrepreneurs: Endeavor Entrepreneur,
EO/GSEA, EY Fellows Program, other support
► Google (NASD: GOOG) become a client @ 5 employees, still a client

01 December 2011 Page 1 Empowering mHealth gazelles

E&Y’s gazelle preserve

80%
of top-20 IPOs since
…and a host of high-caliber, fast- 2007 are E&Y Clients
growing businesses Source: E&Y LLP analysis, November 2011.
Top 20 IPOs in range Jan 1, 2007 – Sep 22, 2011.

► We empower gazelles for success
► How?
► By superserving the client with advisory, tax, audit,
transaction & other services. Try us – we’ll surprise you.
01 December 2011 Page 2 Empowering mHealth gazelles

Nurturing and empowering
the gazelle: a case study
revenue $35.8bn TTM
$ bn

IPO

$0.35bn $3.2bn
$0.0002bn
Not to scale
time
1999 2002 2004 2011

01 December 2011 Page 3 Empowering mHealth gazelles

Tracking gazelles in the wild

01 December 2011 Page 4 Empowering mHealth gazelles

How do you find the next
innovative market leaders? (origination 101)

► If you know the answer, email ► March of the 10,000
JohnD@kpcb.com
5-year aggregate KPI’s
► Volume, engagement, filters
Raw
► Volume: Kiss a lot of frogs leads 10,000
► Engagement: Superserve the
market before they’re clients,
increase as you filter
Qualified
► Filters: VC-style criteria leads 1,000

Pursuits 100
► Apply best practices
Clients 30

10 market leaders
01 December 2011 Page 5 Empowering mHealth gazelles

Gazelle hunting: cast a wide net
(even non-clients end up benefiting, plus adding value to clients)

EYecosystem

EY stealth project #1
coming 1Q 2012

EYclient

EY stealth project #2
coming 1Q 2012

01 December 2011 Page 6 Empowering mHealth gazelles

Gazelles in healthcare innovation

[a more refined
target]

01 December 2011 Page 7 Empowering mHealth gazelles

Spotting the footprints…
health innovation trend watch
Trends A few specific focus areas
► Outcomes-based medicine ► Revenue innovations
► Utilization incentive Outcome incentive
► Decentralization of POC ► Subscription medicine
► Consumerization of healthcare
► Tech: better, faster, cheaper
► Concierge medicine ► Sujoy Guha’s 10 minute, $10 vasectomy
► Desktop gene sequencing
► Consolidation of providers
► Business model innovations
► Making Big Data useful
► Frequently mHealth-enabled
► Global connectivity ► Integrated health systems like McKesson
and Essence Healthcare
► Global virality…not in a good way
► Disruptive technologies
► Disruptive business models

01 December 2011 Page 8 Empowering mHealth gazelles

3 cool /ideas in mHealth
(a “fantasy baseball” VC portfolio)
Does not represent an official endorsement or investment recommendation by Ernst & Young LLP.
Solely a personal opinion of what David Shrier finds interesting this month.
Caveat Emptor.
Ernst & Young LLP may have financial, business or other relationships with one or more of these companies.

Connecting patients Connecting patients Connecting all
and doctors and payers HCPs

► Notice a common theme…?

01 December 2011 Page 9 Empowering mHealth gazelles

On a personal note…my big sister also
speaking about mHealth in December
► Next week’s national mHealth conference, Washington DC
► Harvard’s Center on Media and Child Health (CMCH)

www.CMCH.tv

01 December 2011 Page 10 Empowering mHealth gazelles

> Entrepreneurship starts with “E”.
> Ernst & Young LLP.
David L. Shrier
► Entrepreneur in residence, Ernst & Young LLP

Connect with me:

► @DavidShrier

► david.shrier@ey.com

► 40° 45' 21" North + 73° 59' 11" West
// 5 Times Square, NYC

Photo © 2011 Dianne and David Shrier.
Used with permission.

01 December 2011 Page 11 Empowering mHealth gazelles

Thriving in Any Economy discusses ways for dental practices to succeed even during difficult economic times. It recommends getting back to basics and working smarter by [1] understanding the current economic climate and how dental practices fit within it, [2] recognizing how the new consumer's mindset has been shaped by technology and history, and [3] examining one's own practice personality and making necessary changes to adapt. The document provides strategies for practices such as managing expenses, assigning tasks to reduce the dentist's workload, and embracing change to thrive during uncertain economic periods.

Eldp brochure 2015

BMITA GROUP

This document provides information about the Entrepreneurial Leadership Development Programme, which is a 2-day intensive course held in Nairobi, Kenya from May 29-30, 2015. The course aims to help participants assess their readiness to be entrepreneurs, develop their entrepreneurial mindset and skills, create business plans, and network with other entrepreneurs. Successful participants will receive a 6-month membership to the Institute of Leadership & Management, giving them access to learning resources. The course is designed for experienced professionals looking to start new businesses.

Groupware & Executives

Group Solutions

Indopak igcdp

Adhiraj Singh

Impact of Entrepreneurship on National Development in Jamaica

Stephen Jones

This document discusses the impact of entrepreneurship on national development in Jamaica. It defines entrepreneurship and national development. Entrepreneurship is developing and managing a business to make a profit, while national development improves social welfare through education, healthcare, infrastructure, etc. Positive impacts of entrepreneurship in Jamaica include job creation, regional development, improved standards of living, and overall growth. However, wastage and depletion of resources can also occur. Sociocultural and political/economic factors shape entrepreneurship as well. On balance, entrepreneurs benefit economies through job creation, competition, poverty reduction, and more, though inefficiencies sometimes happen.

Enterpreneurship. 01

Vishnu Sharma

1. The document defines entrepreneurship and discusses key concepts like the definition of an entrepreneur, characteristics of entrepreneurs, types of entrepreneurs, and factors that affect entrepreneurship growth. 2. It also covers topics like the need for entrepreneurship development programs, their objectives and structure, and challenges faced in implementing them. 3. The document concludes by discussing entrepreneurial skills, behaviors, attributes, and the differences between entrepreneurs and professional managers.

Entrepreneurship and project management

chumantrakali

The document discusses the roles of various financial institutions in promoting entrepreneurship in India. It describes the National Institute for Entrepreneurship and Small Business Development (NIESBUD) which aims to support entrepreneurship through training programs and materials. It also outlines the roles of the Small Industries Service Institute (SISI) and District Industries Centre (DIC) in providing technical support, information and incentives to entrepreneurs.

Gazelles_Mfg_casestudies

Santosh Govind Bhosale

This document summarizes several Lean Six Sigma success stories and case studies: 1) Savings of 4 crores/year for a household products company through Design for Six Sigma. Cycle time and cost reductions of $100,000/year for an electronics company. Yield and defect improvements saving $100,000/year for a plastic moulding company. Cost savings of $112,500/year for a process equipment company. 2) OEE and productivity improvements saving $4 million/year for a plastic packaging company in the UAE through integrated Lean Six Sigma implementation. 3) Cost reductions of $1.75 million/year through Design for Six Sigma for redesigning electrical and smoke products.

$100/hour x 2000 hours = $200,000 IPMO Margin (20%) $40,000 Staffing Shop Margin (20%) $40,000 Contractor Rate $80/hour Contractor Pay $160,000 Total Spend $240,000 Over Budget $40,000 MathewsMichaels.com © Copyright 2011 Mathews Michaels Inc. 5 The Independent Danger Winter 2011 So in summary, the “client” budget of $200,000 actually costs $240,000 or 20% more due to the double margins applied. This is not

Keepitpositivegarland

Başak Pillukeit

The document discusses using competitive intelligence to enhance business development. It provides frameworks to combine competitive intelligence (CI) with business development. Specifically, it discusses connecting market analysis and CI insights back to capital assets, current business models, and cash flow to identify implications and scenarios over 1-3 and 3-10 year timeframes. It also discusses techniques like supporting sales and business development teams to connect CI to revenue and profits. The document emphasizes framing horrible scenarios from CI in terms of business opportunities to develop new products and services.

How fit is your capital allocation strategy?

Summary: Even in a time of high biopharma valuations, adopting an activist mentality adds rigor to capital allocation and strategic decision-making, improving not just returns to shareholders but long-term value creation. Therefore, biopharma management teams and boards of directors should proactively assess the “fitness” of their capital allocation strategies and their alignment with operational performance goals by taking an outsider’s view of the business even when times are good — and before a material stumble provides a compelling reason for an outsider to act. For more on this topic, go to http://www.ey.com/GL/en/Industries/Life-Sciences/EY-vital-signs-how-fit-is-your-capital-allocation-strategy.

EBI inVentiv Market Access Virtual Conference

Nathan White, CPC

This document summarizes a virtual conference on market access in the era of specialty and biotech drugs. It notes that by 2016, 8 of the top 10 worldwide drugs will be specialty drugs. It also discusses industry trends of developing more targeted therapies, a substantial pipeline of specialty drugs, and the need to demonstrate value to payers facing high costs. Upcoming sessions at the conference will address recent payment developments like accountable care organizations, comparative effectiveness research, and CMS coverage policies.

Demystifying entrepreneurship, by IMD Professor Benoit Leleux

Sébastien Flury

Marketing Roundtable - March 12th, 2013

AnnArborSPARK

Learn customer identification and positioning strategies from real world case studies. Whether you’re a startup looking for angel money, or a mature company trying to grow, you will find value in the concepts and stories discussed during the hour-long presentation. Find out how to use customer personas to make better marketing decisions that deliver bottom-line results. Leave with a clearer understanding of who your customer is, who your customer isn’t.

社企啄木鳥 Tic100決賽簡報

東翰郭

This document outlines the process and plan for a social enterprise to produce its first benefit report. It discusses gathering input from stakeholders including students, mentors, and social enterprises. It also references frameworks and standards from organizations like B Lab and GRI to guide the report content and production. The document outlines hosting seminars and conducting interviews to research reporting best practices. The social enterprise's goal is to collaborate with a university to complete its first benefit report and pursue B Corp certification, then produce a second report in the future.

CRM, eCRM and "Truth Marketing". EyeForPharma SFE Summit 2008

pdenayer

Vitold Henisz slides: “Financial Returns to Stakeholder Capital: Tying Commun...

Sustainable Brands

This document discusses using the Financial Valuation Tool (FV Tool) to estimate the expected net present values of sustainability investments for Newmont Ghana Gold's Ahafo mine project. The tool helps answer questions about determining the right portfolio of sustainability investments and their potential financial returns. It also supports alignment across different business functions. The document provides examples of sustainability scenarios analyzed in the tool and discusses indirect value protection from mitigating project risks. Quotes from Newmont Ghana Gold employees note improvements in cross-functional collaboration and the sustainability team's ability to articulate business cases in financial terms since using the FV Tool.

Keynote Health Tech Event Eindhoven - Open Innovation Health Tech Opportuntie...

BenHeublKeynotes

Our call for Investment in Startups in 2002.... 16 years on... the time has c...

Ivan Kaye

Nse 5 point gamma final for lk 1-17-13

mobohic

This document discusses Nu Skin, an anti-aging company projected to be a $1 trillion industry by 2025. It outlines Nu Skin's innovative anti-aging skincare and nutrition products, scientific collaborations, record-setting product launches, global growth, and social business model. Distributors can earn commissions averaging over $100,000 with an optional starter package as low as $200 to become a distributor.

AAL Investment Forum 2010 - Financing companies in the new environment – chal...

AALInvestmentForum2010

Keynote on Knowledge Managment - Weggeman

NHTVBreda

The document discusses knowledge management and innovation in the casino industry. It notes that the amount of information in the world doubles every two years and professionals now have 1800 times more information available than in 1980. It also provides three generic strategies for competing in the knowledge economy: product leadership, operational excellence and cost leadership, and customer intimacy. Finally, it discusses how Procter & Gamble experimented with "open innovation" by crowdsourcing solutions to research problems on their website.

Rob Antulov CFO Network presentation

Azure Group

The document discusses raising capital in Australia post-GFC. It notes that while the financial markets were impacted by the GFC, the effects in Australia were relatively mild. Equity capital markets remained active, with over $100 billion raised in 2009. For early stage businesses, sources of capital include angels investors, accelerator programs, venture capital funds, and corporate venture arms. Recent examples are provided of early stage companies raising seed investments. While capital is available, accessing it requires strong deal flow and matching risk profiles.

Nucerity International - The ideal business opportunity!

dphome

A Pulse on the Ecosystem: Where & Why I'd Invest

Angela Tran Kingyens

Social Enterprise: University of Stellenbosch: 7 May 2013

Colin Habberton

Venturefest Bristol 2011, John Clarkson, Atlas Genetics

Science City Bristol

The document summarizes the funding history of Atlas Genetics, a diagnostics company. It received seed funding of £1m in 2005, Series A funding of £2m in 2007, interim funding of £0.5m in 2009, and Series B funding of £18.5m in 2011 from investors including Novartis Venture Funds and J&J Development Corp. The company approached both European and US VCs for funding and was eventually able to build a syndicate including major diagnostic/medical companies for its Series B round after contacting Novartis Venture Funds and J&J Development Corp directly.

Venturefest Bristol 2011, John Clarkson,

Science City Bristol

The document summarizes the funding history of Atlas Genetics, a diagnostics company. It received seed funding of £1M in 2005, Series A funding of £2M in 2007, interim funding of £0.5M in 2009, and Series B funding of £18.5M in 2011 from investors including Novartis Venture Funds and J&J Development Corp. The company approached both European and US VCs for funding and was eventually able to build a syndicate including major diagnostic and pharmaceutical companies to fund its product development and launch.

Public Health Lecture 4 Social Sciences and Public Health

phuakl

STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7

shruti jagirdar

Unit 4: MRA 103T Regulatory affairs This guideline is directed principally toward new Molecular Entities that are likely to have significant use in the elderly, either because the disease intended to be treated is characteristically a disease of aging ( e.g., Alzheimer's disease) or because the population to be treated is known to include substantial numbers of geriatric patients (e.g., hypertension).

Similar to Empowering mHealth Gazelles

Mm Fall Winter201112 All

BradGeddes

Keepitpositivegarland

Başak Pillukeit

How fit is your capital allocation strategy?

EBI inVentiv Market Access Virtual Conference

Nathan White, CPC

Demystifying entrepreneurship, by IMD Professor Benoit Leleux

Sébastien Flury

Marketing Roundtable - March 12th, 2013

AnnArborSPARK

社企啄木鳥 Tic100決賽簡報

東翰郭

CRM, eCRM and "Truth Marketing". EyeForPharma SFE Summit 2008

pdenayer

Vitold Henisz slides: “Financial Returns to Stakeholder Capital: Tying Commun...

Sustainable Brands

Keynote Health Tech Event Eindhoven - Open Innovation Health Tech Opportuntie...

BenHeublKeynotes

Our call for Investment in Startups in 2002.... 16 years on... the time has c...

Ivan Kaye

Nse 5 point gamma final for lk 1-17-13

mobohic

AAL Investment Forum 2010 - Financing companies in the new environment – chal...

AALInvestmentForum2010

Keynote on Knowledge Managment - Weggeman

NHTVBreda

Rob Antulov CFO Network presentation

Azure Group

Nucerity International - The ideal business opportunity!

dphome

A Pulse on the Ecosystem: Where & Why I'd Invest

Angela Tran Kingyens

Social Enterprise: University of Stellenbosch: 7 May 2013

Colin Habberton

Venturefest Bristol 2011, John Clarkson, Atlas Genetics

Science City Bristol

Venturefest Bristol 2011, John Clarkson,

Science City Bristol

Similar to Empowering mHealth Gazelles (20)

Mm Fall Winter201112 All

Keepitpositivegarland

How fit is your capital allocation strategy?

EBI inVentiv Market Access Virtual Conference

Demystifying entrepreneurship, by IMD Professor Benoit Leleux

Marketing Roundtable - March 12th, 2013

社企啄木鳥 Tic100決賽簡報

CRM, eCRM and "Truth Marketing". EyeForPharma SFE Summit 2008

Vitold Henisz slides: “Financial Returns to Stakeholder Capital: Tying Commun...

Keynote Health Tech Event Eindhoven - Open Innovation Health Tech Opportuntie...

Our call for Investment in Startups in 2002.... 16 years on... the time has c...

Nse 5 point gamma final for lk 1-17-13

AAL Investment Forum 2010 - Financing companies in the new environment – chal...

Keynote on Knowledge Managment - Weggeman

Rob Antulov CFO Network presentation

Nucerity International - The ideal business opportunity!

A Pulse on the Ecosystem: Where & Why I'd Invest

Social Enterprise: University of Stellenbosch: 7 May 2013

Venturefest Bristol 2011, John Clarkson, Atlas Genetics

Venturefest Bristol 2011, John Clarkson,

Recently uploaded

Public Health Lecture 4 Social Sciences and Public Health

phuakl

STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7

shruti jagirdar

5 Effective Homeopathic Medicines for Irregular Periods

Dr. Deepika's Homeopathy - Gaur City

Dr. Tan's Balance Method.pdf (From Academy of Oriental Medicine at Austin)

GeorgeKieling1

Home Organization Academy of Oriental Medicine at Austin Academy of Oriental Medicine at Austin Academy of Oriental Medicine at Austin About AOMA: The Academy of Oriental Medicine at Austin offers a masters-level graduate program in acupuncture and Oriental medicine, preparing its students for careers as skilled, professional practitioners. AOMA is known for its internationally recognized faculty, award-winning student clinical internship program, and herbal medicine program. Since its founding in 1993, AOMA has grown rapidly in size and reputation, drawing students from around the nation and faculty from around the world. AOMA also conducts more than 20,000 patient visits annually in its student and professional clinics. AOMA collaborates with Western healthcare institutions including the Seton Family of Hospitals, and gives back to the community through partnerships with nonprofit organizations and by providing free and reduced price treatments to people who cannot afford them. The Academy of Oriental Medicine at Austin is located at 2700 West Anderson Lane. AOMA also serves patients and retail customers at its south Austin location, 4701 West Gate Blvd. For more information see www.aoma.edu or call 512-492-303434.

pharmacy exam preparation for undergradute students.pptx

AdugnaWari

Giloy in Ayurveda - Classical Categorization and Synonyms

Planet Ayurveda

Giloy, also known as Guduchi or Amrita in classical Ayurvedic texts, is a revered herb renowned for its myriad health benefits. It is categorized as a Rasayana, meaning it has rejuvenating properties that enhance vitality and longevity. Giloy is celebrated for its ability to boost the immune system, detoxify the body, and promote overall wellness. Its anti-inflammatory, antipyretic, and antioxidant properties make it a staple in managing conditions like fever, diabetes, and stress. The versatility and efficacy of Giloy in supporting health naturally highlight its importance in Ayurveda. At Planet Ayurveda, we provide a comprehensive range of health services and 100% herbal supplements that harness the power of natural ingredients like Giloy. Our products are globally available and affordable, ensuring that everyone can benefit from the ancient wisdom of Ayurveda. If you or your loved ones are dealing with health issues, contact Planet Ayurveda at 01725214040 to book an online video consultation with our professional doctors. Let us help you achieve optimal health and wellness naturally.

Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW

Get New Sim

Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...

FFragrant

Spontaneous Bacterial Peritonitis - Pathogenesis , Clinical Features & Manage...

Jim Jacob Roy

Call Girls Goa (india) +91-7426014248 Goa Call Girls

sagarvarma453

Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)

MuskanShingari

Statistics- Statistics is the science of collecting, organizing, presenting, analyzing and interpreting numerical data to assist in making more effective decisions. A statistics is a measure which is used to estimate the population parameter Parameters-It is used to describe the properties of an entire population. Examples-Measures of central tendency Dispersion, Variance, Standard Deviation (SD), Absolute Error, Mean Absolute Error (MAE), Eigen Value

2nd-generation Antihistaminic Part I.pptx

Madhumita Dixit

CLASSIFICATION OF H1 ANTIHISTAMINICS- FIRST GENERATION ANTIHISTAMINICS- 1)HIGHLY SEDATIVE-DIPHENHYDRAMINE,DIMENHYDRINATE,PROMETHAZINE,HYDROXYZINE 2)MODERATELY SEDATIVE- PHENARIMINE,CYPROHEPTADINE, MECLIZINE,CINNARIZINE 3)MILD SEDATIVE-CHLORPHENIRAMINE,DEXCHLORPHENIRAMINE TRIPROLIDINE,CLEMASTINE SECOND GENERATION ANTIHISTAMINICS-FEXOFENADINE, LORATADINE,DESLORATADINE,CETIRIZINE,LEVOCETIRIZINE, AZELASTINE,MIZOLASTINE,EBASTINE,RUPATADINE. Mechanism of action of 2nd generation antihistaminics- These drugs competitively antagonize actions of histamine at the H1 receptors. Pharmacological actions- Antagonism of histamine-The H1 antagonists effectively block histamine induced bronchoconstriction, contraction of intestinal and other smooth muscle and triple response especially wheal, flare and itch. Constriction of larger blood vessel by histamine is also antagonized. 2) Antiallergic actions-Many manifestations of immediate hypersensitivity (type I reactions)are suppressed. Urticaria, itching and angioedema are well controlled.3) CNS action-The older antihistamines produce variable degree of CNS depression.But in case of 2nd gen antihistaminics there is less CNS depressant property as these cross BBB to significantly lesser extent. 4) Anticholinergic action- many H1 blockers in addition antagonize muscarinic actions of ACh. BUT IN 2ND gen histaminics there is Higher H1 selectivitiy : no anticholinergic side effects

Can Traditional Chinese Medicine Treat Blocked Fallopian Tubes.pptx

FFragrant

Breast cancer: Post menopausal endocrine therapy

Dr. Sumit KUMAR

Breast cancer in postmenopausal women with hormone receptor-positive (HR+) status is a common and complex condition that necessitates a multifaceted approach to management. HR+ breast cancer means that the cancer cells grow in response to hormones such as estrogen and progesterone. This subtype is prevalent among postmenopausal women and typically exhibits a more indolent course compared to other forms of breast cancer, which allows for a variety of treatment options. Diagnosis and Staging The diagnosis of HR+ breast cancer begins with clinical evaluation, imaging, and biopsy. Imaging modalities such as mammography, ultrasound, and MRI help in assessing the extent of the disease. Histopathological examination and immunohistochemical staining of the biopsy sample confirm the diagnosis and hormone receptor status by identifying the presence of estrogen receptors (ER) and progesterone receptors (PR) on the tumor cells. Staging involves determining the size of the tumor (T), the involvement of regional lymph nodes (N), and the presence of distant metastasis (M). The American Joint Committee on Cancer (AJCC) staging system is commonly used. Accurate staging is critical as it guides treatment decisions. Treatment Options Endocrine Therapy Endocrine therapy is the cornerstone of treatment for HR+ breast cancer in postmenopausal women. The primary goal is to reduce the levels of estrogen or block its effects on cancer cells. Commonly used agents include: Selective Estrogen Receptor Modulators (SERMs): Tamoxifen is a SERM that binds to estrogen receptors, blocking estrogen from stimulating breast cancer cells. It is effective but may have side effects such as increased risk of endometrial cancer and thromboembolic events. Aromatase Inhibitors (AIs): These drugs, including anastrozole, letrozole, and exemestane, lower estrogen levels by inhibiting the aromatase enzyme, which converts androgens to estrogen in peripheral tissues. AIs are generally preferred in postmenopausal women due to their efficacy and safety profile compared to tamoxifen. Selective Estrogen Receptor Downregulators (SERDs): Fulvestrant is a SERD that degrades estrogen receptors and is used in cases where resistance to other endocrine therapies develops. Combination Therapies Combining endocrine therapy with other treatments enhances efficacy. Examples include: Endocrine Therapy with CDK4/6 Inhibitors: Palbociclib, ribociclib, and abemaciclib are CDK4/6 inhibitors that, when combined with endocrine therapy, significantly improve progression-free survival in advanced HR+ breast cancer. Endocrine Therapy with mTOR Inhibitors: Everolimus, an mTOR inhibitor, can be added to endocrine therapy for patients who have developed resistance to aromatase inhibitors. Chemotherapy Chemotherapy is generally reserved for patients with high-risk features, such as large tumor size, high-grade histology, or extensive lymph node involvement. Regimens often include anthracyclines and taxanes.

Gene Expression System-viral gene delivery Mpharm(Pharamaceutics)

MuskanShingari

Gene therapy can be broadly defined as the transfer of genetic material to cure a disease or at least to improve the clinical status of a patient. One of the basic concepts of gene therapy is to transform viruses into genetic shuttles, which will deliver the gene of interest into the target cells. Safe methods have been devised to do this, using several viral and non-viral vectors. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery. The biggest hurdle faced by medical research in gene therapy is the availability of effective gene-carrying vectors that meet all of the following criteria: Protection of transgene or genetic cargo from degradative action of systemic and endonucleases, Delivery of genetic material to the target site, i.e., either cell cytoplasm or nucleus, Low potential of triggering unwanted immune responses or genotoxicity, Economical and feasible availability for patients . Viruses are naturally evolved vehicles that efficiently transfer their genes into host cells. Choice of viral vector is dependent on gene transfer efficiency, capacity to carry foreign genes, toxicity, stability, immune responses towards viral antigens and potential viral recombination. There are a wide variety of vectors used to deliver DNA or oligo nucleotides into mammalian cells, either in vitro or in vivo. The most common vector system based on retroviruses, adenoviruses, herpes simplex viruses, adeno associated viruses.

Tele Optometry (kunj'sppt) / Basics of tele optometry.

Kunj Vihari

Call Girl Pune 7339748667 Vip Call Girls Pune

Mobile Problem

Call Girls Electronic City 🥰 Bangalore Call Girl No Advance Book Now

saftyhealth48

Cluster Mapping of Medical Tourism in Turkey and Regional Clustering for Heal...

Istanbul Beykent University (İstanbul Beykent Üniversitesi)

As the world population is aging, Health tourism has become vitally important and will be increased day by day. Because of the availability of quality health services and more favorable prices as well as to shorten the waiting list for medical services regionally and internationally. There are some aspects of managing and doing marketing activities in order for medical tourism to be feasible, in a region called as clustering in a region with main stakeholders groups includes Health providers, Tourism cluster, etc. There are some related and affecting factors to be considered for the feasibility of medical tourism within this study such as competitiveness, clustering, Entrepreneurship, SMEs. One of the growth phenomenon is Health tourism in the city of Izmir and Turkey. The model of five competitive forces of Porter and The Diamond model that is an economical model that shows the four main factors that affect the competitiveness of a nation and its industries in this study. The short literature of medical tourism and regional clustering have been mentioned.

biomechanics of running. Dr.dhwani.pptx

Dr. Dhwani kawedia

The biomechanics of running involves the study of the mechanical principles underlying running movements. It includes the analysis of the running gait cycle, which consists of the stance phase (foot contact to push-off) and the swing phase (foot lift-off to next contact). Key aspects include kinematics (joint angles and movements, stride length and frequency) and kinetics (forces involved in running, including ground reaction and muscle forces). Understanding these factors helps in improving running performance, optimizing technique, and preventing injuries.

Recently uploaded (20)

Public Health Lecture 4 Social Sciences and Public Health

STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7

5 Effective Homeopathic Medicines for Irregular Periods

Dr. Tan's Balance Method.pdf (From Academy of Oriental Medicine at Austin)

pharmacy exam preparation for undergradute students.pptx

Giloy in Ayurveda - Classical Categorization and Synonyms

Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW

Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...

Spontaneous Bacterial Peritonitis - Pathogenesis , Clinical Features & Manage...

Call Girls Goa (india) +91-7426014248 Goa Call Girls

Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)

2nd-generation Antihistaminic Part I.pptx

Can Traditional Chinese Medicine Treat Blocked Fallopian Tubes.pptx

Breast cancer: Post menopausal endocrine therapy

Gene Expression System-viral gene delivery Mpharm(Pharamaceutics)

Tele Optometry (kunj'sppt) / Basics of tele optometry.

Call Girl Pune 7339748667 Vip Call Girls Pune

Call Girls Electronic City 🥰 Bangalore Call Girl No Advance Book Now

Cluster Mapping of Medical Tourism in Turkey and Regional Clustering for Heal...

biomechanics of running. Dr.dhwani.pptx

Empowering mHealth Gazelles

1. Empowering mHealth gazelles E&Y’s hypergrowth companies practice (SGM) @ mHealthCon, New Brunswick NJ 01 December 2011

2. Fast facts about Ernst & Young LLP Well-known facts: ► Been around a while: since 1849 (including predecessors) ► Global: 150,000+ people in 140+ countries ► Premiere Big4 accounting firm Little-known facts: ► Entrepreneur of the Year for 25 years & Winning Women Entrepreneurs for 4 years ► Heavily involved with emerging economy entrepreneurs: Endeavor Entrepreneur, EO/GSEA, EY Fellows Program, other support ► Google (NASD: GOOG) become a client @ 5 employees, still a client 01 December 2011 Page 1 Empowering mHealth gazelles

3. E&Y’s gazelle preserve 80% of top-20 IPOs since …and a host of high-caliber, fast- 2007 are E&Y Clients growing businesses Source: E&Y LLP analysis, November 2011. Top 20 IPOs in range Jan 1, 2007 – Sep 22, 2011. ► We empower gazelles for success ► How? ► By superserving the client with advisory, tax, audit, transaction & other services. Try us – we’ll surprise you. 01 December 2011 Page 2 Empowering mHealth gazelles

4. Nurturing and empowering the gazelle: a case study revenue $35.8bn TTM $ bn IPO $0.35bn $3.2bn $0.0002bn Not to scale time 1999 2002 2004 2011 01 December 2011 Page 3 Empowering mHealth gazelles

5. Tracking gazelles in the wild 01 December 2011 Page 4 Empowering mHealth gazelles

6. How do you find the next innovative market leaders? (origination 101) ► If you know the answer, email ► March of the 10,000 JohnD@kpcb.com 5-year aggregate KPI’s ► Volume, engagement, filters Raw ► Volume: Kiss a lot of frogs leads 10,000 ► Engagement: Superserve the market before they’re clients, increase as you filter Qualified ► Filters: VC-style criteria leads 1,000 Pursuits 100 ► Apply best practices Clients 30 10 market leaders 01 December 2011 Page 5 Empowering mHealth gazelles

7. Gazelle hunting: cast a wide net (even non-clients end up benefiting, plus adding value to clients) EYecosystem EY stealth project #1 coming 1Q 2012 EYclient EY stealth project #2 coming 1Q 2012 01 December 2011 Page 6 Empowering mHealth gazelles

8. Gazelles in healthcare innovation [a more refined target] 01 December 2011 Page 7 Empowering mHealth gazelles

9. Spotting the footprints… health innovation trend watch Trends A few specific focus areas ► Outcomes-based medicine ► Revenue innovations ► Utilization incentive Outcome incentive ► Decentralization of POC ► Subscription medicine ► Consumerization of healthcare ► Tech: better, faster, cheaper ► Concierge medicine ► Sujoy Guha’s 10 minute, $10 vasectomy ► Desktop gene sequencing ► Consolidation of providers ► Business model innovations ► Making Big Data useful ► Frequently mHealth-enabled ► Global connectivity ► Integrated health systems like McKesson and Essence Healthcare ► Global virality…not in a good way ► Disruptive technologies ► Disruptive business models 01 December 2011 Page 8 Empowering mHealth gazelles

10. 3 cool /ideas in mHealth (a “fantasy baseball” VC portfolio) Does not represent an official endorsement or investment recommendation by Ernst & Young LLP. Solely a personal opinion of what David Shrier finds interesting this month. Caveat Emptor. Ernst & Young LLP may have financial, business or other relationships with one or more of these companies. Connecting patients Connecting patients Connecting all and doctors and payers HCPs ► Notice a common theme…? 01 December 2011 Page 9 Empowering mHealth gazelles

11. On a personal note…my big sister also speaking about mHealth in December ► Next week’s national mHealth conference, Washington DC ► Harvard’s Center on Media and Child Health (CMCH) www.CMCH.tv 01 December 2011 Page 10 Empowering mHealth gazelles

12. > Entrepreneurship starts with “E”. > Ernst & Young LLP. David L. Shrier ► Entrepreneur in residence, Ernst & Young LLP Connect with me: ► @DavidShrier ► david.shrier@ey.com ► 40° 45' 21" North + 73° 59' 11" West // 5 Times Square, NYC Photo © 2011 Dianne and David Shrier. Used with permission. 01 December 2011 Page 11 Empowering mHealth gazelles

Empowering mHealth Gazelles

Recommended

Recommended

More Related Content

Similar to Empowering mHealth Gazelles

Similar to Empowering mHealth Gazelles (20)

Recently uploaded

Recently uploaded (20)

Empowering mHealth Gazelles